Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grunenthal GmbH

www.grunenthal.com

Latest From Grunenthal GmbH

J&J Gambles Oklahoma Opioid Trial Is Better Than Settlement; State Seeks $870m Per Year

In opening statements, Oklahoma suggests award could be 'just shy of $13bn' if it takes 20 years to fix the problem.

Legal Issues Drug Safety

Merck Makes Its Debut In Pain With Pioneering New Analgesic Class

Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.

Innovation Deals

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

A Grunenthal First: Establishing A US Presence With A Tailored Marketing Strategy

Germany's pain-focused specialty pharmaceutical firm is adding America to its commercial reach, through acquiring New York's Averitas Pharma to jumpstart its push to commercialize products on its own account, via a niche approach.

 

Deals Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register